ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 312 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q4 2021. The put-call ratio across all filers is 0.54 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,768,550 | -34.2% | 103,035 | -12.7% | 0.01% | -33.3% |
| Q2 2023 | $4,209,128 | +88.9% | 118,035 | +34.6% | 0.01% | +80.0% |
| Q1 2023 | $2,228,063 | -42.5% | 87,719 | -8.2% | 0.01% | -44.4% |
| Q4 2022 | $3,874,251 | +809.4% | 95,519 | +640.5% | 0.01% | +800.0% |
| Q3 2022 | $426,000 | -6.2% | 12,899 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $454,000 | -58.2% | 12,899 | -45.3% | 0.00% | -50.0% |
| Q1 2022 | $1,085,000 | -88.3% | 23,599 | -83.1% | 0.00% | -88.2% |
| Q4 2021 | $9,282,000 | +6.2% | 140,000 | 0.0% | 0.02% | 0.0% |
| Q3 2021 | $8,740,000 | -29.6% | 140,000 | -6.7% | 0.02% | -29.2% |
| Q2 2021 | $12,423,000 | +368.4% | 150,000 | +275.0% | 0.02% | +380.0% |
| Q1 2021 | $2,652,000 | -77.0% | 40,000 | -73.3% | 0.01% | -80.0% |
| Q4 2020 | $11,510,000 | +167.3% | 150,000 | +50.0% | 0.02% | +127.3% |
| Q3 2020 | $4,306,000 | -20.2% | 100,000 | -20.0% | 0.01% | -21.4% |
| Q2 2020 | $5,399,000 | +25.1% | 125,000 | -16.7% | 0.01% | +7.7% |
| Q1 2020 | $4,316,000 | -61.1% | 150,000 | -14.3% | 0.01% | -51.9% |
| Q4 2019 | $11,100,000 | -7.3% | 175,000 | -58.8% | 0.03% | -6.9% |
| Q3 2019 | $11,977,000 | -48.3% | 425,000 | -51.4% | 0.03% | -50.0% |
| Q2 2019 | $23,188,000 | -8.1% | 875,000 | -36.4% | 0.06% | -7.9% |
| Q1 2019 | $25,231,000 | +47.7% | 1,375,000 | 0.0% | 0.06% | +34.0% |
| Q4 2018 | $17,078,000 | -1.0% | 1,375,000 | +52.8% | 0.05% | +23.7% |
| Q3 2018 | $17,253,000 | -15.6% | 900,000 | -40.1% | 0.04% | -19.1% |
| Q2 2018 | $20,448,000 | +88.6% | 1,503,500 | 0.0% | 0.05% | +88.0% |
| Q1 2018 | $10,840,000 | – | 1,503,500 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WESTERN FINANCIAL Corp | 820,346 | $62,945,000 | 41.38% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,260,869 | $250,206,000 | 32.27% |
| Aquilo Capital Management, LLC | 365,926 | $28,078,000 | 5.84% |
| L1 Capital Pty Ltd | 298,687 | $23,127,000 | 4.32% |
| First Light Asset Management, LLC | 704,449 | $54,052,000 | 4.00% |
| ACUTA CAPITAL PARTNERS, LLC | 139,000 | $10,665,000 | 2.90% |
| Evolutionary Tree Capital Management, LLC | 48,265 | $3,703,000 | 2.82% |
| Parkman Healthcare Partners LLC | 127,171 | $9,758,000 | 2.50% |
| Capital Impact Advisors, LLC | 88,183 | $6,766,000 | 1.66% |
| Tri Locum Partners LP | 56,003 | $4,297,000 | 1.56% |